Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Takashi Nagakubo"'
Autor:
Masaomi Nangaku, Tadao Akizawa, Takashi Nagakubo, Taeko Yonekawa, Toshifumi Kimura, Yukihiro Endo, Alexander Cobitz
Publikováno v:
Therapeutic Apheresis and Dialysis. 26:1065-1078
Daprodustat is an approved treatment for anemia of chronic kidney disease (CKD) in Japan.This post hoc analysis evaluated pooled safety data for daprodustat from 3 phase 3 Japanese studies in dialysis-dependent and nondialysis patients with anemia of
Autor:
Masaomi Nangaku, Reiko Nagai, Kyo Kurata, Yukihiro Endo, Takashi Nagakubo, Hidetoshi Kanai, Nobuhiko Okuda, Alexander R. Cobitz
Publikováno v:
Therapeutic Apheresis and Dialysis. 25:979-987
Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease. This phase 3 study evaluated the efficacy and safety of daprodustat in an uncontrolled cohort of 56 Japanese peritoneal dial
Autor:
Reiko Nagai, Alexander R. Cobitz, Takayuki Hamano, Takashi Nagakubo, Kyo Kurata, Yukihiro Endo, Tadao Akizawa, Nigel P. Jones, Yoshiharu Tsubakihara, Masaomi Nangaku, Nobuhiko Okuda
Publikováno v:
Am J Nephrol
Background: Daprodustat is an oral agent that stimulates erythropoiesis by inhibiting the prolyl hydroxylases which mark hypoxia-inducible factor for degradation through hydroxylation. Its safety and efficacy (noninferiority) were assessed in this 52
Autor:
Ryutaro Shimamura, Debra J. Tompson, Annette S. Gross, Hirofumi Ogura, Takashi Nagakubo, Nicola Scott, Edward P. Cannons, Hiroko Ino, Atsushi Nakano, Michalis Kostapanos, Carwyn Davies, Marcy Powell, Harue Igarashi
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Funder: GlaxoSmithKline; doi: http://dx.doi.org/10.13039/100004330
BACKGROUND AND OBJECTIVES: GSK2982772 is an oral small-molecule RIPK1 inhibitor with potential therapeutic efficacy in immune-mediated inflammatory diseases (IMIDs). An inter-eth
BACKGROUND AND OBJECTIVES: GSK2982772 is an oral small-molecule RIPK1 inhibitor with potential therapeutic efficacy in immune-mediated inflammatory diseases (IMIDs). An inter-eth
Autor:
Hirofumi Ogura, Aili L. Lazaar, Takayuki Iida, Yuki Matsuzawa, Claire Ambery, Akira Wakamatsu, Bruce E. Miller, Yotaro Numachi, Takashi Nagakubo
Publikováno v:
Clinical Pharmacology in Drug Development. 8:1081-1087
Danirixin is a selective and reversible CXC chemokine receptor 2 antagonist that may be useful for the treatment of respiratory diseases such as chronic obstructive pulmonary disease. This study aimed to evaluate the safety, tolerability, and pharmac
Autor:
Hidetoshi Kanai, Masaomi Nangaku, Reiko Nagai, Nobuhiko Okuda, Kyo Kurata, Takashi Nagakubo, Yukihiro Endo, Cobitz, Alexander
Publikováno v:
Therapeutic Apheresis & Dialysis; Dec2021, Vol. 25 Issue 6, p979-987, 9p
Autor:
Hirofumi Ogura, Bruce L. Miller, Yuki Matsuzawa, Akira Wakamatsu, Takashi Nagakubo, Claire Ambery, Yotaro Numachi
Publikováno v:
Clinical Problems.
Autor:
Iida, Takayuki1 (AUTHOR) takayuki.2.iida@gsk.com, Matsuzawa, Yuki1 (AUTHOR), Ogura, Hirofumi1 (AUTHOR), Nagakubo, Takashi2 (AUTHOR), Wakamatsu, Akira3 (AUTHOR), Ambery, Claire4 (AUTHOR), Miller, Bruce E.5 (AUTHOR), Lazaar, Aili L.5 (AUTHOR), Numachi, Yotaro6 (AUTHOR)
Publikováno v:
Clinical Pharmacology in Drug Development. Nov2019, Vol. 8 Issue 8, p1081-1087. 7p.
Autor:
Nangaku, Masaomi, Akizawa, Tadao, Nagakubo, Takashi, Yonekawa, Taeko, Kimura, Toshifumi, Endo, Yukihiro, Cobitz, Alexander
Publikováno v:
Therapeutic Apheresis & Dialysis; Dec2022, Vol. 26 Issue 6, p1065-1078, 14p
Autor:
Tompson, Debra J., Davies, Carwyn, Scott, Nicola E., Cannons, Edward P., Kostapanos, Michalis, Gross, Annette S., Powell, Marcy, Ino, Hiroko, Shimamura, Ryutaro, Ogura, Hirofumi, Nagakubo, Takashi, Igarashi, Harue, Nakano, Atsushi
Publikováno v:
European Journal of Drug Metabolism & Pharmacokinetics; Feb2021, Vol. 46 Issue 1, p71-83, 13p